<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00464243</url>
  </required_header>
  <id_info>
    <org_study_id>EFC6072</org_study_id>
    <secondary_id>EUDRACT : 2006-005303-34</secondary_id>
    <nct_id>NCT00464243</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Volinanserin on Sleep Maintenance Insomnia - Polysomnographic Study</brief_title>
  <acronym>NOCTURNE907</acronym>
  <official_title>Efficacy and Safety of 2 mg/Day M100907 on Sleep Maintenance Insomnia: a 6-week, Multicenter, Randomized, Double-blind, Placebo-controlled Polysomnographic Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess efficacy and safety of volinanserin in the population
      of patients complaining of sleep maintenance insomnia. The patients suffering from that
      condition frequently wake up during the night, their sleep is non restorative and they suffer
      from a significant distress or impairment in their daily activities consecutive to insomnia.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2007</start_date>
  <completion_date type="Actual">January 2008</completion_date>
  <primary_completion_date type="Actual">January 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline to 6 weeks of treatment of the mean night polysomnographic (NPSG) wake time after sleep onset (WASO).</measure>
    <time_frame>6 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Functional Outcomes of Sleep Questionnaire at 6 weeks</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">604</enrollment>
  <condition>Sleep Initiation and Maintenance Disorders</condition>
  <arm_group>
    <arm_group_label>Volinanserin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 mg volinanserin tablets orally once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>tablets orally once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>volinanserin</intervention_name>
    <description>oral administration</description>
    <arm_group_label>Volinanserin</arm_group_label>
    <other_name>M100907</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>oral administration</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of primary insomnia based on Diagnostic and Statistical Manual of Mental
             Disorders (Fourth Edition) criteria

          -  Disturbances of sleep maintenance criteria based on patient's information related to
             sleep pattern during the preceding month

          -  Specific criteria based on the NPSG recordings during the screening nights

        Exclusion Criteria:

          -  Females who are lactating or who are pregnant

          -  Night shift workers, and individuals who nap 3 or more times per week over the
             preceding month

          -  Consumption of xanthine-containing beverages (i.e. tea, coffee, cola) comprising more
             than 5 cups/day

          -  Participation in another trial having received study medication within 1 month before
             the screening visit

          -  Body Mass Index ≥ 33

          -  Use of over-the-counter medications such as tryptophan, valerian root, kava,
             melatonin, St. John's Wort, Alluna or prescription sleep medication

          -  Use of any substance with psychotropic effects or properties know to affect sleep/wake

          -  History of primary hypersomnia, narcolepsy, breathing-related sleep disorder,
             circadian rhythm sleep disorder, parasomnia, dyssomnia

          -  Clinically significant, severe or unstable, acute or chronically progressive medical
             or surgical disorder

          -  Positive qualitative urine drug screen (opiates, cocaine, amphetamine…)

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>ICD CSD</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Bridgewater</city>
        <state>New Jersey</state>
        <zip>08807</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Cove</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Vienna</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Laval</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Russian Federation</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.sanofi-aventis.com</url>
  </link>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 20, 2007</study_first_submitted>
  <study_first_submitted_qc>April 20, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 23, 2007</study_first_posted>
  <disposition_first_submitted>August 4, 2017</disposition_first_submitted>
  <disposition_first_submitted_qc>August 4, 2017</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">August 8, 2017</disposition_first_posted>
  <last_update_submitted>August 4, 2017</last_update_submitted>
  <last_update_submitted_qc>August 4, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 8, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Sleep problems</keyword>
  <keyword>Insomnia</keyword>
  <keyword>Sleeplessness</keyword>
  <keyword>Polysomnographic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sleep Initiation and Maintenance Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Volinanserin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

